View Post

Final Results of the KRISTINE Trial in HER2-Positive Breast Cance

In Clinical Trials by Barbara Jacoby

By: Dave Levitan From: cancernetwork.com Treatment for HER2-positive breast cancer with trastuzumab emtansine (T-DM1) plus pertuzumab yielded a higher risk of event-free survival (EFS) events compared with trastuzumab, pertuzumab, and chemotherapy, according to a phase III trial. There was a similar risk of invasive disease–free survival (IDFS) events, though, suggesting that chemotherapy may be unnecessary in some patients. The standard …

View Post

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Alice Melão From: breastcancer-news.com The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …

View Post

New medicine reduces the risk of breast cancer recurring by 50 percent, researchers say

In In The News by Barbara Jacoby

By: Reba Hollingsworth From: wtvr.com Thirty-eight-year-old Ticiana Machado is going through her second round of chemotherapy. The wife and mother of two was diagnosed with breast cancer two months ago. “How you doing? How you feeling?” said Dr. Mary Helen Hackney. Ticiana’s doctor Mary Helen Hackney with VCU Massey Cancer Center says a new drug combo may help patients like …

View Post

Cancer Research Highlight: Puma Biotech’s Basket Pays Off

In Clinical Trials by Barbara Jacoby

By: Zach Hartman From: seekingalpha.com Summary Puma Biotechnology is known almost exclusively as a breast cancer company. New basket study results may portend a move outside of there, but you have to think outside the box. How relevant are HER2 mutations, though? Puma Biotechnology (PBYI) has made its entire game up on the back of one drug, a “pan-HER” inhibitor …